FORM FOR NOTIFICATION OF PARTICIPATION AND POSTAL VOTING AT ANNUAL GENERAL MEETING ON 5 JUNE 2024

This form must be received by ExpreS2ion Biotech Holding AB (publ) no later than 30 May 2024.

Note that shareholders whose shares are nominee-registered must register the shares in their own name in order to vote. Shareholders should inform their nominees well in advance before 30 May 2024. Instructions for this can be found in the notice of the Annual General Meeting.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in ExpreS2ion Biotech Holding AB (publ), reg. no. 559033-

3729, at the Annual General Meeting on 5 June 2024. The voting right is exercised in accordance with the voting options marked below.

Name of shareholder	Personal ID number / date of birth/Registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board director, the CEO or a signatory of the shareholder and solemnly declare that I am authorized to submit this postal vote on behalf of the shareholder and that the contents of the postal vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

Telephone number	Telephone number
Place and date	
Signature*	
Clarification of signature	

Instructions:

- Complete all the requested information above
- Select the preferred voting options below regarding how the shareholder wishes to vote
- Print, fill in, sign and send the form in original to ExpreS2ion Biotech Holding AB (publ), "AGM 2024", c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, Sweden. The completed and

^{*} In case of signing on behalf of a legal entity, the name of the signatory shall be printed next to the signature and an up-to-date certificate of registration (or a similar document) shall be attached to the proxy form.

- signed form may also be submitted electronically by e-mail to investor@expres2ionbio.com (with reference "AGM 2024").
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under Signature above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign.
- A power of attorney shall be enclosed if the shareholder votes in advance by proxy. If the shareholder is a legal entity, a registration certificate or a corresponding document for the legal entity shall be enclosed with the form.

Further information regarding postal voting

The board of directors of ExpreS2ion Biotech Holding AB (publ) has, in accordance with the company's articles of association, resolved that the shareholders of ExpreS2ion Biotech Holding AB (publ), at the Annual General Meeting on 5 June 2024 shall be able to exercise their voting rights by postal voting.

Shareholders cannot give any other instructions than selecting one of the voting options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, please refrain from selecting a voting option. A vote (i.e. the postal vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

Only one form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form, or a form without valid authorisation documentation, may be discarded without being considered.

The postal voting form must be received by the company no later than 30 May 2024. A postal vote can be withdrawn up to and including 30 May 2024 by contacting the company by e-mail to investor@expres2ionbio.com (with reference "AGM 2024") or by post to ExpreS2ion Biotech Holding AB (publ), "AGM 2024", c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, Sweden, att: Keith Alexander.

For complete resolutions and proposals for resolutions, please refer to the notice and the other documents to the Annual General Meeting available on the company's website. The resolutions and the proposed resolutions set out in the notice and other documents to the Annual General Meeting may be changed or withdrawn. ExpreS2ion Biotech Holding AB (publ) will disclose such adjustments through a press release, after which the shareholders have the right to submit a new form.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammorengelska.pdf.

Annual general meeting in ExpreS2ion Biotech Holding AB (publ) on 5 June 2024

The options below comprise the proposals submitted by the board of directors and the shareholders which are included in the notice convening the annual general meeting.

The voting list proposed to be approved under item 2 below is the voting list prepared by the company, based on the shareholders' register on the record date of the general meeting and the advance votes received, and as verified by the person elected to attest the minutes.

The tasks of the person elected to approve the minutes also include verifying the voting list and that the advance votes received are correctly reflected in the minutes.

1. Opening of the meeting and election of chairman of the meeting Emil Hedberg
Yes 🗆 No 🗀
2. Preparation and approval of voting list
Yes 🗆 No 🗆
4. Determination of whether the meeting has been duly convened
Yes 🗆 No 🗆
5. Approval of the agenda
Yes 🗆 No 🖂
6. Presentation of the annual report and auditor's report and the group annual report and group auditor's report
Yes 🖂 No 🖂
7a. Resolution regarding adoption of income statement and balance sheet and the group income statement and the group balance sheet
Yes 🔲 No 🖂
7b. Resolution regarding he profit or loss of the Company in accordance with the adopted balance sheet
Yes 🗆 No 🗆
7c. Resolution regarding discharge from liability for the board of directors and the managing director
7c. Martin Roland Jensen
Yes 🔲 No 🖂
7c. Karin Garre
Yes 🗆 No 🗀
7c. Jakob Knudsen

Yes 🖂 No 🖂
7c. Sara Sande
Yes 🗆 No 🖂
7c. Bent Frandsen (CEO)
Yes No No
8. Determining of the number of directors, deputy directors, auditors and deput auditors
Number of directors Four
Yes 🗆 No 🖂
Number of auditors One registered accounting firm
Yes 🖂 No 🖂
9. Determining the fees for the board of directors and the auditor
Fees for the directors SEK 625,000 in total, SEK 250,000 to the chairman and SEK 125,000 to the other directors
Yes 🖂 No 🖂
Fees for the auditors In accordance with approved invoice
Yes 🖂 No 🖂
10. Election of the board of directors and the auditors
10. Re-election of Martin Roland Jensen
Yes 🖂 No 🖂
10. Re-election of Karin Garre
Yes 🖂 No 🖂
10. Re-election of Jakob Knudsen
Yes 🖂 No 🖂
10. Re-election of Sara Sande
Yes 🖂 No 🖂
10. Re-election of Martin Roland Jensen as chairman of the board
Yes 🖂 No 🖂

10. Re-election of the registered audit firm Ernst & Young Aktiebolag
Yes 🗆 No 🗀
11. Resolution to amend the articles of association
Yes 🗆 No 🗀
12. Resolution to approve the board of directors' resolution on a new issue of shares and warrants ("Units)
Yes 🗆 No 🖂
13. Resolution regarding incentive program 2024/2027 for senior executives and employees through issuance of warrants and approval of transfer of the warrants
Yes 🗆 No 🗀
14. Resolution regarding authorization for the board to issue shares, convertibles and/or warrants
Yes 🖂 No 🖂
15. Resolution to amend the articles of association
Yes 🗆 No 🗅